Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 257
- 试验地点
- 74
- 主要终点
- The primary efficacy endpoint is vessel patency at 12 months.
研究概览
简要总结
This is a clinical study of a new self-expanding stent (FlexStent®) designed specifically to cope with the extreme demands of the superficial femoral artery (SFA)/proximal popliteal artery. The arteries are often abbreviated as femoropopliteal.
The intent of this study is to demonstrate that the FlexStent® Femoropopliteal Self-Expanding Stent System is safe and effective for the treatment of patients with peripheral arterial disease. Specifically, the FlexStent® shall meet or exceed the proposed safety and efficacy performance goals established for Femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 35 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All subjects must meet the following criteria:
- •Subjects, male or female, must be at least 35 years of age at the time of consent. A female of childbearing potential may be enrolled, provided she has a negative pregnancy test within 7 days of screening.
- •Subjects must give written informed consent prior to participation in the study and must understand the purpose of this study and be willing to adhere to the study procedures described in this protocol.
- •Rutherford Classification Category 2-4
- •De novo lesion in the Femoropopliteal artery, including the entire extent of the superficial femoral artery and the proximal portion of the popliteal artery extending to the medial condyle 3 cm above the knee joint
- •Disease segment length ≤ 180 mm
- •>70% diameter stenosis and/or occlusion based on site-determined visual angiography
- •Patent ipsilateral iliac artery
- •Patency of ipsilateral mid/distal popliteal artery and at least 1 tibial artery with no planned intervention
- •Target reference vessel diameter 3.5-7.5 mm.
- •Projected life expectancy of 12 months or greater
- •Patient is available for follow-up for 36 months and is willing and able to comply with all follow-up requirements
- •Patient is willing and able to provide signed informed consent
排除标准
- •Any subject meeting any of the following criteria will be excluded from the study.
- •Target vessel previously treated with a stent
- •Target lesion within 1.5 cm of the ostium of the SFA
- •Rutherford Classification Category 0,1,5 or 6
- •Inability to tolerate antithrombotic or antiplatelet therapies
- •Pregnancy (female of child-bearing age confirmed pregnant)
- •Other comorbidity risks which in the opinion of the investigator limit longevity or likelihood of complying with protocol follow up.
- •Serum creatinine > 2.5 mg/dL
- •Myocardial infarction or stroke within 30 days of treatment date
- •Known hypercoagulable state
- •Known bleeding diathesis
- •Untreated angiographically-evident thrombus in target vessel
- •Patients currently enrolled in any other clinical trial
研究组 & 干预措施
PAD
This is a prospective single-arm multi-center clinical trial designed to evaluate the safety and efficacy of the Flexible Stenting Solutions Flext Stent® Femoropopliteal stenting system in subjects with lower limb peripheral arterial desease (PAD). Subjects targeted for enrollment must have a single de-novo lesion located in the superficial femoral artery and/or proximal popliteal artery with at > 70% stenosis. Subjects must meet all enrollment criteria and provide written informed consent prior to participation in the study.
干预措施: FlexStent® Femoropopliteal Self Expanding Stent System (Device)
结局指标
主要结局
The primary efficacy endpoint is vessel patency at 12 months.
时间窗: 12 Months
The primary efficacy endpoint is vessel patency at 12 months. Vessel patency is defined as freedom from a greater than 50% restenosis in the stented segment as determined by the DUS peak systolic velocity ratio (PSVR) comparing data within the treated segment to the proximal normal arterial segment and freedom from clinically-driven TLR within the stented segment within 1 year of the procedure.
The primary safety endpoint is freedom from all cause death, TLR, or index limb amputation through 30 days.
时间窗: 30 Days
The primary safety endpoint is defined as freedom from all cause death, index limb amputation and target lesion revascularization (TLR) through 30 days. The proportion of patients remaining free from this composite endpoint will be compared to a safety performance goal for bare nitinol stents.
次要结局
未报告次要终点